Category: Redefining Every Stage Investments (RESI)
The Redefining Every Stage Investments (RESI) Conference is an ongoing conference series that provides an international venue for life science companies across Biotech, Medtech, Diagnostics and Healthcare IT and to source investors from around the globe, create relationships, and eventually, secure funding.
For the first time, the Redefining Early Stage Investments (RESI) Conference is coming to San Diego, CA. On Monday June 19th, of Bio week, RESI will provide an opportunity to start your week at the Westin San Diego Gaslamp Quarter with up to 16 face to face meetings with the most relevant global investors for your technology. Not only that, but 3 full-day program tracks of investor panels and workshops will help scientist-entrepreneurs learn the ins and outs of early stage fundraising issues.
RESI’s early bird rate ends tomorrow. If you are headed to BIO and want to achieve maximum ROI on your trip to San Diego, get your RESI pass today.
For its first trip to San Diego, the Redefining Early Stage Investments (RESI) conference team will be bringing with it a content rich agenda. RESI’s Biotech and Medtech tracks will feature over 75 investor speakers across 16 panels devoted to specific investor types, technology sectors, or new issues in fundraising. Representatives from family offices, big pharma, VC, angels and more will share with the audience the types of opportunities they are currently looking for as well as what it is like to be on the other side of the negotiating table.
RESI’s Early Stage Workshops track features 4 entrepreneur education workshops, including a new session on 505(b)(2) Strategy led by Ken Phelps, CEO of Camargo.
With our Asia-North America Track, one of our newer and most popular additions, attendees will get the chance to hear directly from investors and strategic partners from across the Pacific looking for North American innovation. These panels will be a must-see for any fundraising entrepreneur in the sector.
We are very excited to bring this diverse pool of investors and speakers to San Diego to share their expertise and experience with the hundreds of fundraising scientist-entrepreneurs who attend RESI. While many of our speaking spots are already allocated, if you or someone you know would want to participate please don’t hesitate to reach out.
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series
RESI’s first MaRS landing was in Summer 2016, and the success of the event revealed a tremendous appetite for an early stage life science investment venue in Toronto.
For 2017, RESI on MaRS built on its initial success to become the centerpiece of the new Toronto Health Innovation Week – a sequence of summits, conferences and receptions that gathered together the most vital players in Toronto’s healthcare ecosystem. As RESI continues its cycle of events throughout North America, we look forward to working with local bio-med innovation hubs in every RESI city to showcase their innovations and technology resources.
Last week’s RESI on MaRS grew significantly over our 2016 event. Delegates came to RESI from 12 countries. There was a 25% increase in investor attendance. In all, more than 600 attendees came to RESI on MaRS to pitch their ideas or to find new investment opportunities.
More bandwidth was added for RESI Partnering meetings – RESI attendees exchanged over 3000 meeting requests, and 1000 scheduled one-on-one meetings took place. Outside of RESI Partnering, the halls of MaRS Discovery District buzzed with ad-hoc meetings and networking encounters.
30 companies competed in the RESI Innovation Challenge. The victor, Steadiwear, was a MaRS portfolio company.
Partnering Forum
RESI on MaRS also featured three full tracks of content. In RESI’s 16 investor panels, attendees heard from a wide variety of early stage investors and strategic players who are looking to Toronto for new technology opportunities. Some panels focused on a particular funding source such as Family Offices, Public Private Partnerships and Corporate Venture Capital. Others looked at the diversity of the investment landscape in a specific technology vertical, such as Diagnostics or Medical Devices. Meanwhile, the Tales From The Road panel – seasoned life science CEOs who have recent experience of raising capital – spoke about how they’d met the challenge of attracting global investors to back their Canadian startups.
Incubator Accelerator New Models Panel (Ying Tam, Managing Director Health, MaRS Discovery District | Frédéric Lemaitre Auger, Senior Director, Investments, Accel-Rx – Canada’s Health Science Accelerator | Rebecca Yu, Head of JLABS @ Toronto, Johnson & Johnson Innovation | Randy Yatscoff, Executive Vice President, Business Development, TEC Edmonton | Kristi Ebong, Head Strategy Business Development, Cedars-Sinai Health System)
The RESI Asia-North America Partnering Track was added to the event, drawing high level decision makers from healthcare investment firms and major healthcare corporations from China, Japan, Korea, and Taiwan. These investors defined their interest in investing in healthcare startups in Canada and the US, and explained how to work with a partner in Asia to reach a new marketplace and grow your company.
Asia Pharma Partners Panel (Hiroshi Kawai, Vice President, Mitsubishi Tanabe Holdings America | Tianle Redanz, Director of Business Development, Simcere of America | Weiyong Sun, Senior Director External Scientific Affairs, Daiichi Sankyo | Richard Soll, Senior Vice President, Research Service Division (RSD), WuXi AppTec)
It’s clear that Toronto has a strong ecosystem for generating new healthcare technologies and launching new companies, and RESI on MaRS has served as a catalyst to join those new technologies with relevant, active investors who see the advantages of investing in Canada. By building these new bridges between technology and capital, RESI on MaRS will move science forward in Toronto.
RESI’s next stop will be in San Diego on Monday June 19th – the first RESI event to take place concurrent with the BIO International Convention. If you’d like to join LSN for a day of investor meetings, new panel content and high level networking, you can register now.
Your idea may be brilliant but is your marketing collateral doing it justice? LSN is launching a contest to find out. This week, we’d like to see your logo and tagline. Send in your logo and tell us the 5-7 word tagline for your startup, and we’ll feature the best submissions in a future edition of this newsletter, which will go out to 40,000 readers around the world. It’s a fantastic platform to reach investors and strategic partners interested in your space.
In our years of working with early stage life science companies we’ve observed that companies that lack consistent, concise messaging often lose what would otherwise be interested investors simply because they couldn’t understand your core value prop or they misunderstood what you are working on. And it all starts from the logo and tagline.
Your marketing package needs to convey, concisely and consistently, who you are and what your company does. A logo therefore visually represents your company’s brand. The tagline then distills your company’s vision down into its most concise form – generally 5-7 words.
Additionally, a fully developed marketing package should include an elevator pitch, an executive summary, and a pitch deck, with a website that builds on all these elements to showcase your company. We’ll explore these elements in future editions.
Check out our guide on how a great set of marketing collateral is structured. In the meantime, send LSN your logo and tagline – we’ll offer our professional opinion, and will share our favorites in a future issue of Next Phase.
The 13th Redefining Early Stage Investments (RESI) Conference will take place in San Diego on Monday June 19th, 2017 during the 2017 BIO week. RESI SD will offer early stage companies and investors an opportunity to get the most out of the busy week when the biotech and medtech world gathers in San Diego.
Why RESI?
500+ early stage investors seeking innovations across therapeutics, medical device, diagnostics and healthcare IT
Meet with 10 categories of early stage global investors
Great ROI – 16 to 20 meetings in one day that are a fit for your stage of development & product
24investor panels and entrepreneur workshops covering a wide variety of topics
Kick off your BIO week at a unique investor-centric gathering for early stage companies
Venue: The Westin San Diego Gaslamp Quarter, 910 Broadway Circle, San Diego, CA 92101
About RESI
RESI is a venue for entrepreneurs to meet with 10 categories of investors that LSN tracks including Family Offices, Corporate Venture Funds, Angel Groups, Venture Philanthropy, Venture Capital and more. Through the RESI Partnering, fundraising executives can have up to 16 scheduled meetings as well as many more ad-hoc meetings with diverse life science investors who fit their company’s technology sector, indication and stage of development. Additionally, through an expansive series of panels and workshops, attendees will have the chance to hear firsthand accounts from investors explaining their current investment mandates and process for identifying and qualifying candidates.
On April 4, more than 600 entrepreneurs and investors entered the exhibition hall at MaRS Discovery District in Toronto. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. Here, LSN would like to present the top 3 winners who attracted the greatest amount of “RESI Cash”.
First Place: Steadiwear
Steadiwear inc.‘s mission is to restore independence and quality of life to all tremor sufferers worldwide. We have developed the Steadiglove, a smart glove that responsively stabilizes hand tremors in Essential Tremor and Parkinson’s disease using novel vibration damping technology. This allows users to go about all daily activities such as eating and getting dressed with significantly less frustration.
Michael Quigley, VP of Market Research, Life Science Nation | Mark Elias, CEO, Co-founder, Steadiwear | Emile Maamary, CFO, Co-founder | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation
Second Place: BlueLight
BlueLight is a healthcare technology company specializing in the measurement of light energy. Our data-driven technologies, sold worldwide, target a quality gap in the multi billion-dollar dental composite market.
Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation | Michael Quigley, VP of Market Research, Life Science Nation | JP Furey, CEO, BlueLight | Peter MacLareN, Director of Customer Relations, BlueLight
Third Place: Cyclica
Cyclica Inc. has developed, validated, and patented a structure-based proteome-wide screening platform, Ligand Express™, that currently features PROBEx (proteome-screening), SWITCHx (ligand effect prediction) and DIVEx (systems biology & drug-protein interactomes). Ligand Express™ is unique in that it is a drug-centric platform. For a small molecule ligand, Ligand Express™ automatically generates an intelligent list of ligand-protein interactions by searching through a large proprietary database of all available structurally characterized proteins. The platform provides a panoramic view of a small molecule ligand to better understand on- and off-target interactions, and is valuable in finding novel desirable or undesirable targets. By gaining insights into a ligand’s polypharmacology, Cyclica’s clients can identify unknown targets, prioritize lead candidates, elucidate adverse effects, and understand repurposing opportunities.
Michael Quigley, VP of Market Research, Life Science Nation | Naheed Kurji, President and CEO, Cyclica | Natasha Eldridge, Marketing Manager – RESI Conference, Life Science Nation
Thank you to all who competed in the RESI on MaRS Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.
By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN
The Asia Pacific region represents a diverse healthcare marketplace, where each country comes with a unique set of challenges including regulatory approval, reimbursement, distribution channels, and healthcare practice. North American startups can benefit from working with strategic partners who could help them navigate the complex landscape. Corporations from Asia Pacific are also strongly motivated to seek collaborators from overseas.
In the biopharma field, Japanese big pharmaceutical companies have entered the global biopharma arena through M&A since 1980s. Now armed with strong R&D capability, they are looking to collaborate with biotech startups and commercialize their products globally. Chinese pharmaceutical firms are jumping into the fray in recent years, with an aim to modernize China’s pharma industry and obtain an entry portal to advanced economy markets.
Opportunities are abundant within HealthTech. Many investment groups from Asia are focusing on medical devices, diagnostics, and genomics that are faced with lower risks and shorter development time. In addition, traditional IT, manufacturing, and food industries in Asia are looking to break into healthcare. By working with them, entrepreneurs could also gain support in software development, engineering, prototyping, and manufacturing.
RESI Toronto provides an excellent opportunity for entrepreneurs to meet potential Asian partners face-to-face. Two exciting panels are organized on pharma and HealthTech, respectively:
Asia Pharma Partners
Richard Soll, Senior Vice President, International Discovery Service Unit, WuXi AppTec (Moderator)
Weiyong Sun, Senior Director External Scientific Affairs, Daiichi Sankyo
Next Phase Newsletter 